DePuy Synthes signs exclusive distribution agreement with CGBIO for NOVOSIS

DePuy Synthes entered an exclusive distribution agreement with CGBIO for NOVOSIS, an advanced bone graft substitute containing growth factors, for spine, craniomaxillofacial, and trauma portfolios in the United States, Canada, and Australia.

“Separately, it has entered an exclusive distribution agreement with CGBIO for NOVOSIS, an advanced bone graft substitute containing growth factors, across its spine, craniomaxillofacial, and trauma portfolios.”g-medtech.com

• 2 sources
• g-medtech.comDePuy Synthes Announces Two Strategic Agreements to Expand Orthopaedic Portfolio - News CenterMay 27, 2026
• healthindustryhub.com.auDePuy Synthes strikes deal ahead of split from Johnson & Johnson - Health Industry HubHealth Industry HubJun 16, 2026

Summarized from public sources; check the original articles before acting on it.